NxStage Medical, Inc. (NXTM) President Sells $27,560.00 in Stock
NxStage Medical, Inc. (NASDAQ:NXTM) President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $27.56, for a total value of $27,560.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NxStage Medical, Inc. (NASDAQ:NXTM) traded down 0.25% during midday trading on Wednesday, hitting $27.49. The stock had a trading volume of 671,334 shares. The company’s market cap is $1.81 billion. NxStage Medical, Inc. has a 52 week low of $20.45 and a 52 week high of $30.80. The stock’s 50 day moving average price is $28.01 and its 200-day moving average price is $25.82.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same period in the prior year, the firm earned ($0.03) earnings per share. The company’s quarterly revenue was up .0% compared to the same quarter last year. Equities research analysts predict that NxStage Medical, Inc. will post ($0.05) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “NxStage Medical, Inc. (NXTM) President Sells $27,560.00 in Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/04/nxstage-medical-inc-nxtm-president-sells-27560-00-in-stock.html.
A number of brokerages have commented on NXTM. Jefferies Group LLC downgraded NxStage Medical from a “buy” rating to a “hold” rating and decreased their target price for the company from $33.00 to $30.00 in a research note on Tuesday, August 8th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a research note on Thursday, August 10th. BTIG Research downgraded NxStage Medical from a “buy” rating to a “neutral” rating in a research note on Friday, August 11th. Northland Securities restated a “hold” rating and issued a $30.00 target price on shares of NxStage Medical in a research note on Monday, August 7th. Finally, Canaccord Genuity downgraded NxStage Medical from a “buy” rating to a “hold” rating and set a $30.00 target price for the company. in a research note on Monday, August 7th. One equities research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the company. The company has a consensus rating of “Hold” and an average price target of $30.25.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in NxStage Medical in the first quarter valued at approximately $140,000. Ameritas Investment Partners Inc. acquired a new stake in NxStage Medical in the first quarter worth $148,000. Quantitative Systematic Strategies LLC acquired a new stake in NxStage Medical in the second quarter worth $203,000. Amalgamated Bank raised its holdings in NxStage Medical by 7.1% in the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock worth $210,000 after purchasing an additional 553 shares during the period. Finally, Menta Capital LLC acquired a new stake in NxStage Medical in the first quarter worth $212,000. Institutional investors and hedge funds own 92.66% of the company’s stock.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.